Dr Ana Sureda speaks to ecancer about managing Hodgkin lymphoma during the COVID-19 outbreak.
She initially explains some of the problems surrounding transplants during the COVID pandemic, including transplant availability, immunosuppressive consequences, and also the practicalities of receiving a transplant.
Dr Sureda then discusses how best to treat a patient during this time, and what toxicities and co-morbidities doctors must be aware of, providing a few examples.
She also explains generally the way that her hospital and colleagues have been managing cancer patients around the coronavirus pandemic, including safety and isolation protocol.
Finally Dr Sureda explores the use of checkpoint inhibitors, and how COVID has affected the way these treatments are prioritised.
This programme has been supported by an unrestricted educational grant from Takeda.